Search Results - "Bryan, Locke J"

Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial by Bryan, Locke J, Casulo, Carla, Allen, Pamela B, Smith, Scott E, Savas, Hatice, Dillehay, Gary L, Karmali, Reem, Pro, Barbara, Kane, Kaitlyn L, Bazzi, Latifa A, Chmiel, Joan S, Palmer, Brett A, Mehta, Jayesh, Gordon, Leo I, Winter, Jane N

“…To our knowledge, this is the first clinical trial designed to investigate concurrent treatment with a checkpoint inhibitor and conventional chemotherapy in…”
Get more information

Update on the role of copanlisib in hematologic malignancies by Le, Thuy, David, Jerel, Bryan, Locke J.

“…Clinical research in hematologic malignancies is continually advancing with emerging concepts in therapy and evolving results from clinical protocols…”
Get full text

Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy by Aboelella, Nada S, Brandle, Caitlin, Okoko, Ogacheko, Gazi, Md Yeashin, Ding, Zhi-Chun, Xu, Hongyan, Gorman, Gregory, Bollag, Roni, Davila, Marco L, Bryan, Locke J, Munn, David H, Piazza, Gary A, Zhou, Gang

“…BackgroundAdoptive cell therapy (ACT) using genetically modified T cells has evolved into a promising treatment option for patients with cancer. However, even…”
Get full text

Tumefactive fibroinflammatory lesion successfully treated with Rituximab by Bishop, Jessica L, Bryan, Locke J., Savage, Natasha M., Byrd, J. Kenneth

“…Skull base pseudotumors, or tumefactive fibroinflammatory lesions (TFIL), are tumors characterized by local destruction with benign histopathology. Treatment…”
Get full text

Why is My Patient Anemic? by Bryan, Locke J., MD, Zakai, Neil A., MD, MSc

“…Anemia is a decreased number of circulating red blood cells and is a common medical condition faced in clinical practice. Anemia is caused by loss of red blood…”
Get full text

Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib by Andrick, Benjamin, Alwhaibi, Abdulrahman, DeRemer, David L., Quershi, Sameera, Khan, Rahil, Bryan, Locke J., Somanath, Payaningal R., Pantin, Jeremy

Get full text

Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy by Bryan, Locke J, Gordon, Leo I

“…Abstract Immunotherapy remains an important tool for treatment of hematologic malignancies. The Programmed Death-1 (PD-1) immune checkpoint pathway has emerged…”
Get full text

When Baking Soda Goes on Shortage: Urine Alkalinization With Acetazolamide and Oral Sodium Bicarbonate by Whiteside, Hoyle, Gandhi, Arpita, Ajebo, Germame, Bryan, Locke J.

Get full text

A 43-Year-Old Woman With Hoarseness of Voice and Chest Pressure by Miles, Matthew J., Dillard, Thomas A., Bryan, Locke J.

“…A 43-year-old woman with a medical history of cervical cancer treated with curative hysterectomy 12 years earlier developed progressive dyspnea, chest…”
Get full text

Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date by Mensah, Felix A, Blaize, Jean-Pierre, Bryan, Locke J

“…The importance of the phosphatidylinositol-3-kinase (PI3K) pathway in cell survival and proliferation has made it an attractive target in cancer therapy. The…”
Get full text

Factors predicting survival in peripheral T‐cell lymphoma in the USA: a population‐based analysis of 8802 patients in the modern era by Petrich, Adam M., Helenowski, Irene B., Bryan, Locke J., Rozell, Shaina A., Galamaga, Robert, Nabhan, Chadi

“…Summary Current prognostic models for peripheral T‐cell lymphoma (PTCL) have multiple limitations, and questions exist regarding applicability to current…”
Get full text

Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial by Bryan, Locke J., Casulo, Carla, Allen, Pamela, Smith, Scott E., Savas, Hatice, Karmali, Reem, Pro, Barbara, O'Shea, Kaitlyn, Chmiel, Joan, Palmer, Brett Alan, Mehta, Jayesh, Gordon, Leo I., Winter, Jane N.

“…▪ Introduction: Approximately 30-35% of patients with classic Hodgkin Lymphoma will prove refractory to frontline therapy or relapse subsequently. Traditional…”
Get full text

Pidilizumab in the treatment of diffuse large B-cell lymphoma by Bryan, Locke J, Gordon, Leo I

“…The programmed death-1 (PD-1) immune checkpoint pathway is an emerging target in the treatment of hematologic malignancies. Pidilizumab is an mAb that binds to…”
Get more information

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma by Halwani, Ahmad S., Panizo, Carlos, Isufi, Iris, Herrera, Alex F., Okada, Craig Y., Cull, Elizabeth H., Kis, Bela, Chaves, Jorge M., Bartlett, Nancy L., Ai, Weiyun, de la Cruz-Merino, Luis, Bryan, Locke J., Houot, Roch, Linton, Kim, Briones, Javier, Chau, Ian, von Keudell, Gottfried R., Lu, Hailing, Yakovich, Adam, Chen, Michael, Meulen JH, ter, Yurasov, Sergey, Hsu, Frank J., Flowers, Christopher R.

“…Intratumoral injection of G100, a toll-like receptor 4 (TLR4) agonist, was shown pre-clinically to stimulate anti-tumor immune responses and tumor regression…”
Get full text

Releasing the Brake on the Immune System: The PD-1 Strategy for Hematologic Malignancies by Bryan, Locke J, Gordon, Leo I

“…Manipulation of the immune system as a viable cancer treatment strategy has re-emerged. The programmed death 1 (PD-1) pathway is an important, physiologic…”
Get more information

Higher soluble P-selectin is associated with chronic venous insufficiency: The San Diego Population Study by Bryan, Locke J, Callas, Peter W, Criqui, Michael H, Cushman, Mary

“…Abstract Introduction P-selectin is a cell adhesion molecule shown to play a role in venous thromboembolism. We evaluated whether higher P-selectin is…”
Get full text

Persistent indolent pancolonic marginal zone lymphoma of MALT-type with plasmacytic differentiation – A rare post-transplant lymphoma? by Chaffin, Joanna M, Savage, Natasha M, Sharma, Suash, Bryan, Locke J, Raffeld, Mark, Jaffe, Elaine S

“…Abstract Marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is associated with chronic inflammatory disorders. We present an indolent…”
Get full text

Impact of Qualified Dedicated APL Leukemia Specialist and Simplified Treatment Algorithm on Early Deaths in APL, a Monocenter Experience by Kubiak, Michal Jakub, Jillella, Anand P., Bradshaw, Danielle, Savage, Natasha M., Bryan, Locke J., Kolhe, Ravindra, Kota, Vamsi K.

Get full text

Musculoskeletal Pain Syndrome in a Subset of APL Patients during Induction Therapy by Kubiak, Michal Jakub, Jillella, Anand P., Bradshaw, Danielle, Savage, Natasha M., Kolhe, Ravindra, Bryan, Locke J., Kota, Vamsi K.

Get full text

Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience by Shoukier, Mahran, Kota, Vamsi, Kolhe, Ravindra, Bryan, Locke J., Jillella, Anand P, Cortes, Jorge E.

“…Background:Internal tandem duplications (ITDs) within the FMS-like tyrosine kinase 3 (FLT3) gene (FLT3-ITD) is a common driver mutation and confers a poor…”
Get full text